Osimertinib-Resistant Cell Lines and Models
Despite the robust clinical activity exerted by osimertinib, a majority of patients eventually exhibit disease progression while receiving this drug. Resistance to osimertinib includes both on-target and off-target mechanisms. With the use of osimertinib for advanced EGFR-mutant NSCLC increasing, the development of targeted therapies toward osimertinib resistance represents an unmet medical need. To support research in this area, WuXi AppTec offers an extensive panel of validated, osimertinib-resistant cell lines and in vivo models.
Check out our comprehensive platform of drug-resistant models by clicking HERE.
Genetically engineered Osimertinib-resistant cell lines and models
Related Content
What if a constructed PROTAC with a confirmed high-affinity warhead doesn't work as expected? That means we need to take...
VIEW RESOURCEFragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...
VIEW RESOURCE